Shares of DexCom Inc. slipped 3.69% to $69.47 Thursday, on what proved to be an all-around poor trading session for the stock ...
Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...
Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former ...
Zacks Investment Research on MSN1d
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 ApprovalDexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the ...
A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...
The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...
The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...
DexCom (NasdaqGS:DXCM) witnessed a 4% increase in its share price over the past week, as the company announced a significant integration of its G7 Continuous Glucose Monitoring Systems with Nanowear's ...
Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NexGel Inc (NXGL – Research Report) and Dexcom ...
Bringing a game of this magnitude from the home of Connacht Rugby in the Dexcom Stadium in Galway is not only huge for the ...
DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback